| Mrs Lamia Saeed Khan, MD | |
|
1324 Lakeland Hills Blvd, Lakeland, FL 33805-4543 | |
| (863) 687-1321 | |
| (863) 284-1730 |
| Full Name | Mrs Lamia Saeed Khan |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 26 Years |
| Location | 1324 Lakeland Hills Blvd, Lakeland, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154529980 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 244498 (New York) | Secondary |
| 207RI0200X | Internal Medicine - Infectious Disease | ME 103615 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lakeland Regional Medical Center | Lakeland, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lakeland Regional Health Systems Inc | 8325952914 | 346 |
News Archive
The SENSA® Weight-Loss System continues its commitment to giving back with the launch of its "Share Because You Care" charity contest. As part of the SENSA® CARES charity initiative, "Share Because You Care" empowers users to support their favorite causes for the opportunity to win $250 for the non-profit organization of their choice, plus an additional $250 for themselves.
Teleflex Incorporated, a leading global provider of medical technology products, today announced that it has entered into a definitive agreement to sell the Actuation business of its subsidiary Telair International Incorporated to TransDigm Group, Incorporated (NYSE: TDG) for approximately $94 million. The transaction is subject to receipt of Hart-Scott-Rodino approval and other customary closing conditions and is expected to close by the end of 2010.
Molecular biologists at Jefferson's Kimmel Cancer Center in Philadelphia have detailed the cascade of cellular events behind some potentially dangerous autoinflammatory diseases.
Nearly one million people in the UK are living with heart failure, and this is set to rise by 50% over the next couple of decades.
Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.
› Verified 5 days ago
| Entity Name | Lakeland Regional Health Systems Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497748743 PECOS PAC ID: 8325952914 Enrollment ID: O20031118000384 |
News Archive
The SENSA® Weight-Loss System continues its commitment to giving back with the launch of its "Share Because You Care" charity contest. As part of the SENSA® CARES charity initiative, "Share Because You Care" empowers users to support their favorite causes for the opportunity to win $250 for the non-profit organization of their choice, plus an additional $250 for themselves.
Teleflex Incorporated, a leading global provider of medical technology products, today announced that it has entered into a definitive agreement to sell the Actuation business of its subsidiary Telair International Incorporated to TransDigm Group, Incorporated (NYSE: TDG) for approximately $94 million. The transaction is subject to receipt of Hart-Scott-Rodino approval and other customary closing conditions and is expected to close by the end of 2010.
Molecular biologists at Jefferson's Kimmel Cancer Center in Philadelphia have detailed the cascade of cellular events behind some potentially dangerous autoinflammatory diseases.
Nearly one million people in the UK are living with heart failure, and this is set to rise by 50% over the next couple of decades.
Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Lamia Saeed Khan, MD 1324 Lakeland Hills Blvd, Attn: Medical Staff Office, Lakeland, FL 33805-4543 Ph: () - | Mrs Lamia Saeed Khan, MD 1324 Lakeland Hills Blvd, Lakeland, FL 33805-4543 Ph: (863) 687-1321 |
News Archive
The SENSA® Weight-Loss System continues its commitment to giving back with the launch of its "Share Because You Care" charity contest. As part of the SENSA® CARES charity initiative, "Share Because You Care" empowers users to support their favorite causes for the opportunity to win $250 for the non-profit organization of their choice, plus an additional $250 for themselves.
Teleflex Incorporated, a leading global provider of medical technology products, today announced that it has entered into a definitive agreement to sell the Actuation business of its subsidiary Telair International Incorporated to TransDigm Group, Incorporated (NYSE: TDG) for approximately $94 million. The transaction is subject to receipt of Hart-Scott-Rodino approval and other customary closing conditions and is expected to close by the end of 2010.
Molecular biologists at Jefferson's Kimmel Cancer Center in Philadelphia have detailed the cascade of cellular events behind some potentially dangerous autoinflammatory diseases.
Nearly one million people in the UK are living with heart failure, and this is set to rise by 50% over the next couple of decades.
Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.
› Verified 5 days ago
Dr. Elijah Kim, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1324 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-687-1321 Fax: 863-284-1786 | |
Dr. Julia Mcneice, DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7190 Fax: 866-264-8519 | |
Christian Abreu-ramirez, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1324 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-687-1100 | |
Robert H Bevis, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7190 Fax: 866-264-8519 | |
Dr. Lilliam S. Chiques-colon, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7000 Fax: 866-264-8519 | |
Dr. Lijian Wang, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7000 Fax: 866-264-8519 | |
Eric Lipson, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7190 Fax: 866-264-8519 |